

A photograph of two male sprinters in a starting crouch on a blue track. The sprinter in the foreground is wearing a black singlet and is in a more advanced crouch, while the one behind him is wearing a blue singlet. The background shows a blurred stadium with tiered seating.

METRONIDAZOLE

IV 500mg/100ml



DETERMINED TO BE THE FIRST

METRONIDAZOLE

IV 500mg/100ml

Broad spectrum¹

Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections.

Gram-positive anaerobes

Clostridium species.

Eubacterium species.

Peptococcus species.

Peptostreptococcus species.

Gram-negative anaerobes

Bacteroides fragilis group (*B. fragilis*, *B. distasonis*, *B. ovatus*, *B. thetaiotaomicron*, *B. vulgatus*).

Fusobacterium species.

Indications and dosage²

	Loading Dose	Maintenance dose	Notes	Duration
Treatment of Anaerobic Bacterial Infections	15 mg/kg infused over 1 hour (approximately 1 g for a 70 kg adult).	7.5 mg/kg infused over 1 hour every 6 hours (approximately 500mg for a 70 kg adult).	The first maintenance dose should be instituted 6 hours following the initiation of the loading dose.	7 to 10 days.*
Surgical prophylactic use	15 mg/kg infused over 1 hour (approximately 1 g for a 70 kg adult).	7.5 mg/kg infused over 30 to 60 minutes at 6 and 12 hours after the initial dose.	Initial preoperative dose be completed approximately 1 hour before surgery so that adequate drug levels are present in the serum and tissues at the time of initial incision.	On the day of surgery only.

Parenteral therapy may be changed to oral (metronidazole) when conditions warrant, based upon the severity of the disease and the response of the patient to I.V. treatment.

* Infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment. A maximum of 4 g should not be exceeded during a 24-hour period.

DETERMINED TO BE THE FIRST

Unique?³

METRONIDAZOLE

IV 500mg/100ml

High manufacturing quality

- Container is designed as per the QbD* principle.
- Solution is filled and sealed by using advanced aseptic process, without human interventions.
- Total filling process is completed in few seconds.

High Stability

- Product stability is as per ICH** global standard and approved by MOH, UAE.
- Special container size, shape and structure. (Container is with less head space in the container and minimum entrapped air, therefore less oxidation (additional chemicals are not used as stabilizer).

Abbreviation

*QbD - Quality by Design

**ICH - International Conference on Harmonisation

References

- 1 <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a7276a00-bb2f-4876-b58b-f2e953d716e4&type=display>
- 2 <http://www.rxlist.com/flagyl-injection-drug.htm>
- 3 Data on file



GULF INJECT LLC

(Julphar Group of company)

P O Box 61128, Jabel Ali Free Zone, Dubai, United Arab Emirates.

Tel.: +971 4 8817557 Fax: +971 4 88 17862

e-mail: glfinjct@emirates.net.ae

